Home/Filings/4/0001628280-24-008977
4//SEC Filing

Daly Jason B. 4

Accession 0001628280-24-008977

CIK 0001723128other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 4:54 PM ET

Size

19.0 KB

Accession

0001628280-24-008977

Insider Transaction Report

Form 4
Period: 2024-03-03
Daly Jason B.
EVP, Chief Legal Officer
Transactions
  • Exercise/Conversion

    Class A Common Stock

    2024-03-03+22,64537,126 total
  • Tax Payment

    Class A Common Stock

    2024-03-03$5.47/sh7,166$39,19829,960 total
  • Exercise/Conversion

    Class A Common Stock

    2024-03-03+38,22668,186 total
  • Tax Payment

    Class A Common Stock

    2024-03-03$5.47/sh10,864$59,42657,322 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-0322,64545,290 total
    Class A Common Stock (22,645 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-0338,226114,679 total
    Class A Common Stock (38,226 underlying)
  • Award

    Restricted Stock Units

    2024-03-04+143,519143,519 total
    Class A Common Stock (143,519 underlying)
  • Award

    Performance-Based Restricted Stock Units

    2024-03-04+287,038287,038 total
    Class A Common Stock (287,038 underlying)
Footnotes (8)
  • [F1]Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
  • [F3]Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
  • [F4]On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
  • [F5]On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
  • [F6]The restricted stock units vest in four equal annual installments beginning on March 4, 2025.
  • [F7]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
  • [F8]Represents a performance-based restricted stock unit grant of 143,519 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period.

Issuer

Amneal Pharmaceuticals, Inc.

CIK 0001723128

Entity typeother

Related Parties

1
  • filerCIK 0001906486

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 4:54 PM ET
Size
19.0 KB